Sixty Degree Capital

We are a European family office owned fund; we understand biosciences and medical technologies better than anyone else in the Private Equity and Venture Capital ecosystem. The capital of this fund has been generated by the family office's active bioscience investments across Europe, USA, and the APAC region since 1995. We understand the intricacies of commercializing bioscience discoveries. We also acknowledge that bioscience venture leadership requires deep courage - from founders and the investors that back them. What we look for We operate globally and only review investment opportunities submitted to us by our partner investment banks across the globe. If we believe in the transformative power of the discovery and the founder's ambition, this will suffice for us to determine the venture's potential. Our approach Upon receipt of a proposal from our investment bank partners, we will analyze the proposed deal, meet with the venture founders, and understand their vision. We will propose a deal size and structure. Execute a letter of intent and perform appropriate due diligence, negotiate, and execute a mutually acceptable binding contract. Release the required funding, close the transaction and work together to grow the business.

At StartUp Health, we are impact-driven entrepreneurs and investors building a global army of thousands of Health Transformers collaborating to achieve health moonshots --- from ending cancer and curing disease, like diabetes and Alzheimer’s, to delivering quality care to everyone in the world regardless of location or income. We believe that investing in and supporting a diversified global portfolio of health moonshot companies is the key to improving the health and wellbeing of humanity, while also generating healthy financial returns for investors. Since 2012, we’ve made more than 400 investments in companies across 27 countries, and currently have a portfolio of 260+ active companies. We have a flexible, work-from-anywhere policy as our team is fully remote, with team members in NYC, San Francisco, Los Angeles, Baltimore, and Philadelphia. We are open to candidates across the U.S. Benefits include health insurance and long-term disability coverage, 401k with employer matching, employee stock options, and generous time off policy including paid holidays.

Our expertise in biopharma and biotech investments. With decades of experience and a robust network within the biopharma and biotech industries, our team offers unparalleled insight into the scientific and financial landscapes. We are dedicated to identifying transformative therapies and supporting companies that are pioneering the future of healthcare. Empowering entrepeneurs to build leading companies Biovance Capital works closely with entrepreneurs to build leading companies with transformative treatments for patients in need. Stage: We invest in early-stage companies at seed and Series A rounds across Europe, with a focus in Southern countries. Technology: We invest in biotech companies developing therapeutics in any modality and therapeutic area. We require robust and appropriate preclinical models and patented or patentable assets before investing. Market: Large target market with a clear regulatory pathway for approval, with favorable reimbursement and pricing policies. Exit Potential: Sectors with VC/M&A or IPO activity, featuring profitable exits and multiple potential acquirers. Sustainability: During the due diligence process, sustainability risks are taken into account, and whenever identified, mitigation measures are proposed.

K2HV’s investment professionals bring together substantial experience across multiple verticals in healthcare finance and operations, as well as considerable scientific knowledge. Our diverse backgrounds and experience give us a deep understanding of the needs of innovative healthcare companies throughout their lifecycles, and underpin our innovative and creative approach to investing. Our leadership team has committed more than $4 billion to over 100 private and public companies in the life sciences and healthcare industries. High Impact Investments, Long-Term ViewUniquely flexible, permanent capital structure enables us to provide long-term financing solutions and meet the evolving capital needs of growing companies Broad investment mandate allows us to be creative with financing structures Primary focus on customized debt financings, but able to invest in equity as well

Trinity Innovation Bioventure Singapore is a licensed biomed venture capital fund focusing on innovation and value investment with deep insight and experience on Asia markets. We are part of the Trinity Innovation Fund group, founded in 2018, managing multiple VC funds in the region. We are an experienced team led by industrial veterans who have managed multiple VC funds and invested over dozens of biotech companies. Our StrengthAccess to China market through synergy with TIF: Two organizations, One Team Multi-dimensional value-added post investment to enhance possibility of success and returns Clear investment thesis: In Asia, for Global; Leverage regional synergy and realize future value Best-in-class team in biomed investment with strong track record Our Focus TIBS seeks to invest and build great companies that emerging biotechnology leads to innovative therapeutics to address global unmet medical needs. We focus on incubating and growing potential early-stage biotech start-ups with breakthrough platform technology, differentiated scientific merit and commercial value. Our Core CompetencyValue Discovery: Select investment projects based on precise judgements from in-depth research Project Incubation: Incubate cutting-edge science or outstanding entrepreneurs with innovative approaches. Unique incubation strategy: project management by investment team to increase the asset value; management team recruitment to maximize the equity value and capital efficiency Help entrepreneurs to grow rapidly with proprietary foresight, industry understanding and resources

We are Lumira Ventures. $450M+ Invested: Over more than two decades, our firm has invested over $1B via multiple investment funds. $70B+ Cumulative Revenue of Portfolio Company Products: The 40+ products brought from discovery to market by our portfolio companies have generated over $60B of cumulative revenue. 100+ Companies Funded: We leverage the lessons learned from helping create, finance and build over 100 innovative healthcare companies. 27+ Average Years Partner Experience: Our portfolio companies take advantage of one of the most experienced and stable team of venture capital partners in North America. 1B+ Patients Worldwide: The areas of medical need being tackled by our companies include diabetes, Alzheimer’s, vision loss, heart failure, asthma, infectious disease and others that impact the daily lives of over 1 billion people worldwide. Focus Geography: Canada and U.S. Stage: Mix of early, clinical and revenue stage companies that are both privately held and publically traded Sectors: Biotechnology, medical technologies, digital health and consumer healthcare solutions Strategy Lumira executes a consistent, proven investment strategy as a lead investor and active partner with our portfolio companies. We focus on companies whose products offer transformative (not incremental) improvements to patient health outcomes, and the promise of dramatic reductions in the cost of healthcare delivery. Our Canadian heritage helps us “skate to where the puck is going to be,” investing in the new science and clinical insights that we expect will be driving the next decade of patient care. Differentiation Since our inception, we’ve been a different type of venture capital investor. We often focus on backing companies in regions of North America bypassed by most other investors. We manage right-sized funds where the financial interests of our fund investors are tightly aligned with our own. And we differentiate ourselves to entrepreneurs as an investor-of-choice by helping them leverage our multi-decade team stability, global industry relationships and lessons learned from building over 100 companies over our careers.